AGM
BPMC

Alpine Global Management’s Blueprint Medicines BPMC Stock Holding History

Alpine Global Management’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-3,000
Closed -$226K – 122
2017
Q4 		$226K Buy
+3,000
New +$211K 0.05% 126

Other funds holding BPMC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
TGI
TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return

Alpine Global Management's BPMC Position: Q1 2018 in Review

Alpine Global Management sold out of Blueprint Medicines (BPMC) in Q1 2018, closing a stake of 3,000 shares — an estimated $226K sold.

Alpine Global Management first reported a position in BPMC in Q4 2017 and held it in 1 quarter. The position peaked at $226K in Q4 2017. 175 funds tracked by Wall St. Rank hold BPMC as of Q1 2018.

  • Alpine Global Management reported no remaining Blueprint Medicines position as of Q1 2018 after selling out during the quarter.
  • Alpine Global Management sold 3,000 Blueprint Medicines shares in Q1 2018, an estimated $226K.
  • Alpine Global Management first reported a position in Blueprint Medicines in Q4 2017 and held it in 1 quarter.
  • Alpine Global Management's Blueprint Medicines position peaked at $226K in Q4 2017.
  • 175 funds tracked by Wall St. Rank held Blueprint Medicines as of Q1 2018.

Based on Alpine Global Management's 13F filing for Q1 2018, filed 16 May 2018.